WT1 peptide cancer vaccine composition for mucosal administration

Patent metadata

Field	Value
Publication number	US-10206985-B2
Application number	US-201414166970-A
Country	US
Kind code	B2
Filing date	Jan 29, 2014
Priority date	Feb 5, 2013
Publication date	Feb 19, 2019
Grant date	Feb 19, 2019

Abstract

The present invention provides a cancer vaccine composition for mucosal administration for inducing cellular immunity, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a cellular immunity induction promoter. The composition efficiently induces cellular immunity against a cancer in a subject.

First claim

What is claimed is:

1. A method for inducing cellular immunity in a subject, which comprises mucosally administering to the subject a cancer vaccine composition comprising:
(i) a WT1 peptide and/or a modified WT1 peptide;
(ii) a first cellular immunity induction promoter comprising a TLR7 ligand and a helper peptide.

2. The method according to claim 1 , wherein the helper peptide is peptide-25.

3. The method according to claim 2 , wherein the WT1 peptide is Db126 peptide.

4. The method according to claim 1 , wherein the WT1 peptide is Db126 peptide.

5. The method according to claim 1 , wherein mucosally administering comprises orally administering.

6. The method according to claim 1 , wherein mucosally administering comprises sublingual administering.

7. The method according to claim 1 , wherein mucosally administering comprises nasally administering.

8. The method according to claim 1 , wherein the vaccine composition is in the form of a film preparation.

9. The method according to claim 1 , wherein the vaccine composition is in the form of a liquid formulation.

10. The method according to claim 1 , wherein the vaccine composition is in the form of an orally-disintegrating tablet.

11. The method according to claim 1 , wherein the TLR7 ligand is TLR7-II or resiquimod.

12. The method according to claim 11 , wherein the TLR7 ligand is TLR7-II.

13. The method according to claim 11 , wherein the TLR7 ligand is resiquimod.

14. The method according to claim 11 , wherein the helper peptide is peptide-25.

15. The method according to claim 14 , wherein the WT1 peptide is Db126 peptide.

16. The method according to claim 11 , wherein the WT1 peptide is Db126 peptide.

17. The method according to claim 11 , wherein mucosally administering comprises orally administering.

18. The method according to claim 11 , wherein mucosally administering comprises sublingual administering.

19. The method according to claim 11 , wherein mucosally administering comprises nasally administering.

20. The method according to claim 11 , wherein the vaccine composition is in the form of a film preparation.

21. The method according to claim 11 , wherein the vaccine composition is in the form of a liquid formulation.

22. The method according to claim 11 , wherein the vaccine composition is in the form of an orally-disintegrating tablet.

Assignees

• Nitto Denko Corp
• Univ Osaka

Inventors

• Asari Daisuke
• Matsushita Kyohei
• Okazaki Arimichi
• Maeda Yoshiki
• Okubo Katsuyuki
• Hori Mitsuhiko
• Sugiyama Haruo

Classifications

• A61K2039/80

  Vaccine for a specifically defined cancer · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61K9/006

  Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays · CPC title

• A61K2039/541

  Mucosal route · CPC title

• A61K9/0043 Primary

  Nose · CPC title